Immunis Appoints Mark Cabato as Chief Business Officer
Immunis Chairman Dr. Hans Keirstead to Present at the BIO International Convention
Dr. Keirstead is recognized for his groundbreaking work in regenerative medicine and will Co-Chair a workshop with Dr. Gayathri Swaminath, Senior Vice President of Discovery at Juvena Therapeutics. They will lead a discussion on the current regulatory landscape of aging and disease management. Immunis recognizes the underappreciated role of cellular secretomes in regulating human health and has focused its efforts on establishing a space for secretomes as a therapeutic for age-related diseases.
Immunis is a leading force in the field of biomedical innovation and Dr. Keirstead will present Immunis’ cutting-edge secretome development pipeline and current application in a Phase 1/2a clinical trial for patients with muscle atrophy associated with knee osteoarthritis. Immunis hopes to offer unique insights in developing novel secretome-based therapeutics. We invite you to join us in this important discourse, as Immunis continues to push the boundaries of biomedical science.
Dr. Keirstead will also provide the Chairman’s closing remarks. Dr. Keirstead’s extensive involvement in the Age-Related Disease Therapeutics Summit underscores his commitment to spearheading advancements in the fight against age-related diseases.
About Age-Related Disease Therapeutics Summit
The 5th Age-Related Disease Therapeutics Summit is dedicated to advancing the research, development, and understanding of therapeutic approaches in treating age-related disease. For more information, please visit: https://age-related-disease.com
About Immunis Inc.
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.
###